The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

Metabolism: Clinical and Experimental

Volumn 49, Issue 3, 2000, Pages 411-417

  Shimaya, Akiyoshi ^a   Kurosaki, Eiji ^a   Nakano, Ryosuke ^a   Hirayama, Reiko ^a   Shibasaki, Masayuki ^a   Shikama, Hisataka ^a  

^a Inst for Drug Discovery Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[4 [(3,5 DIOXO 1,2,4 OXADIAZOLIDIN 2 YL)METHYL]PHENOXY]BUT 2 ENE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID BINDING PROTEIN; GLUCOSE; MESSENGER RNA; ORAL ANTIDIABETIC AGENT; OXADIAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; YM 440;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIPOGENESIS; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0034021443     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(00)90440-2     Document Type: Article

References (35)

1. Edelman SV: Importance of glucose control. Med Clin North Am 82:665-687, 1998
2. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045. Diabetes 31:1549-1558, 1988
3. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
4. Schwartz S, Raskin P, Fonseca V, et al: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998
5. Matthaei S, Reibold JP, Hamann A, et al: In vivo metformin treatment ameliorates insulin resistance: Evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 133:304-311, 1993
6. Stumvoll M, Nurjahan N, Perriello G, et al: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
7. Serrano Rios M: Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 28:14-18, 1998 (suppl 2)
8. Berger M: Risk of obesity in type II diabetes mellitus. Int J Obes Relat Metab Disord 4:S29-S33, 1992 (suppl)
9. Speigelman BM: PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
10. Lambe KG, Tugwood JD: A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 239:1-7, 1996
11. Shimaya A, Kurosaki E, Shioduka K, et al: YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm Metab Res 30:543-548, 1998
12. Shimaya A, Noshiro O, Hirayama R, et al: Insulin sensitizer YM268 ameliorates insulin resistance by normalizing the decreased content of GLUT4 in adipose tissue of obese Zucker rats. Eur J Endocrinol 137:693-700, 1997
13. Noshiro O, Hirayama R, Shimaya A, et al: Role of plasma insulin concentration in regulating glucose and lipid metabolism in lean and obese Zucker rats. Int J Obes Relat Metab Disord 21:115-121, 1997
14. Bemlohr DA, Angus CW, Lane MD, et al: Expression of specific mRNA during adipose differentiation: Identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci USA 81:5468-5472, 1984
15. Ezaki O, Flores-Riveros JR, Kaestner KH, et al: Regulated expression of an insulin-responsive glucose transporter (GLUT4) minigene in 3T3-L1 adipocytes and transgenic mice. Proc Natl Acad Sci USA 90:3348-3352, 1993
16. Robb JA, Huebner K: Effect of cell chromosome number on simian virus 40 replication. Exp Cell Res 81:120-126, 1973
17. Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci US A 91:7355-7359, 1994
18. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
19. Prochazka M, Premdas FH, Leiter EH, et al: Estrone treatment dissociates primary versus secondary consequences of "diabetes" (db) gene expression in mice. Diabetes 35:725-728, 1986
20. Like AA, Chick WL: Studies in the diabetic mutant mouse. I. Light microscopy and radioautography of pancreatic islets. Diabetologia 6:207-215, 1970
21. Fujiwara T, Wada M, Fukuda K, et al: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/sJ-db/db mice. Metabolism 40:1213-1218, 1991
22. Diani AR, Peterson T, Sawada GA, et al: Ciglitazone, a new hypoglycemic agent. IV. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice. Diabetologia 27:225-234, 1984
23. Lehmann JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953-12956, 1995
24. Young PW, Buckle DR, Cantello BC, et al: Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284:751-759, 1998
25. Rebuffé-Scrive M, Surwit R, Feinglos M, et al: Regional fat distribution and metabolism in a new mouse model (C57BL/6J) of non-insulin-dependent diabetes mellitus. Metabolism 42:1405-1409, 1993
26. Onodera T, Yoon JW, Brown KS, et al: Evidence for a single locus controlling susceptibility to virus-induced diabetes mellitus. Nature 274:693-696, 1978
27. Yamashita S, Nakamura T, Shimomura I, et al: Insulin resistance and body fat distribution. Diabetes Care 19:287-291, 1996
28. Okuno A, Tamemoto H, Tobe K, et al: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
29. Hallakou S, Doaré L, Foufelle F, et al: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rats. Diabetes 46:1393-1399, 1997
30. Kletzien RF, Foellmi LA, Harris PKW, et al: Adipocyte fatty acid - binding protein: Regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol 42:558-562, 1992
31. Reginato MJ, Bailey ST, Krakow SI, et al: A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 273:32679-32684, 1998
32. Paulik MA, Buckholz RG, Lancaster ME, et al: Development of infrared imaging to measure thermogenesis in cell culture: Thermogenic effects of uncoupling protein-2, troglitazone, and β-adrenoceptor agents. Pharm Res 6:944-949, 1998
33. Digby JE, Montague CT, Sewter CP, et al: Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 47:138-141, 1998
34. Shimokawa T, Kato M, Watanabe Y, et al: In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice. Biochem Biophys Res Commun 251:374-378, 1998
35. Foellmi-Adams LA, Wyse BM, Herron D, et al: Induction of uncoupling protein in brown adipose tissue: Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent. Biochem Pharmacol 52:693-701, 1996